pMel17 is recognised by monoclonal antibodies NKI-beteb, HMB-45 and HMB-50 and by anti-melanoma CTL (original) (raw)

• Experimental Oncology
• Published: 01 May 1996

British Journal of Cancer volume 73, pages 1044–1048 (1996)Cite this article

• 210 Accesses
• 23 Citations
• 9 Altmetric
• Metrics details

Abstract

Recently, we cloned the cDNA encoding the melanocyte lineage-specific antigen gp100 and demonstrated that gp100 is recognised by three different monoclonal antibodies (MAbs) used to diagnose malignant melanoma. In addition, we showed that tumour-infiltrating lymphocytes (TIL 1200) from a melanoma patient reacted specifically with cells transfected with the gp100 cDNA. Molecular characterisation of the gp100 cDNA revealed that the gp100 antigen is highly homologous, but not identical, to another melanocyte-specific protein, pMel17. Here, we report that cells transfected with pMel17 cDNA also react with all three MAbs used to diagnose malignant melanoma, NKI-beteb, HMB-45 and HMB-50. Moreover, pMel17 transfectants are specifically lysed by TIL1200. These data demonstrate that antigenic processing of both gp100 and pMel17 give rise to peptides seen by anti-melanoma cytotoxic T lymphocytes (CTL) and are therefore potential targets for immunotherapy of malignant melanoma.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 24 print issues and online access

$259.00 per year

only $10.79 per issue

Buy this article

• Purchase on SpringerLink
• Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

• Log in
• Learn about institutional subscriptions
• Read our FAQs
• Contact customer support

Similar content being viewed by others

Author information

Authors and Affiliations

1. Department of Tumour Immunology, University Hospital Nijmegen St. Radboud, The Netherlands
   GJ Adema

Authors

1. GJ Adema
   You can also search for this author inPubMed Google Scholar
2. ABH Bakker
   You can also search for this author inPubMed Google Scholar
3. AJ de Boer
   You can also search for this author inPubMed Google Scholar
4. P Hohenstein
   You can also search for this author inPubMed Google Scholar
5. CG Figdor
   You can also search for this author inPubMed Google Scholar

Rights and permissions

About this article

Cite this article

Adema, G., Bakker, A., de Boer, A. et al. pMel17 is recognised by monoclonal antibodies NKI-beteb, HMB-45 and HMB-50 and by anti-melanoma CTL.Br J Cancer 73, 1044–1048 (1996). https://doi.org/10.1038/bjc.1996.202

Download citation

• Issue Date: 01 May 1996
• DOI: https://doi.org/10.1038/bjc.1996.202

This article is cited by